Swedish study maps rare cancer complication that kills lymphoma patients

Researchers tracked a deadly immune disorder called hemophagocytic lymphohistiocytosis that strikes cancer patients, documenting its incidence and survival rates across Sweden. The findings could help clinicians recognize and treat the condition faster—a critical factor since early intervention directly affects patient survival.

Originaltitel: Malignancy-associated hemophagocytic lymphohistiocytosis in Sweden: incidence, clinical characteristics, and survival